Immunotherapy has revolutionized treatment of advanced hepatocellular carcinoma (HCC).
In addition, several phase III trials of immunotherapy in early-to intermediate-stage HCC in …

The emerging field of immuno-oncology has brought exciting developments in the treatment
of hepatocellular carcinoma (HCC). It has also raised urgent questions about the role of …

Liver transplantation (LT) is a highly curative therapy for patients with hepatocellular
carcinoma (HCC). However, due to the shortage of donor livers and rapid progression of …

Liver transplantation (LT) has emerged as a curative strategy for hepatocellular carcinoma
(HCC), but contributes to a higher predisposition to HCC recurrence in the …

Hepatocellular carcinoma (HCC) is a malignancy that requires multidisciplinary evaluation
to develop individualized and tailored treatment concepts. While liver resection and …

Background Multiple systemic therapy options have been recently approved for the
treatment of hepatocellular carcinoma (HCC). In particular, immuno-oncology combination …

Initial concerns about graft rejection, with ICIs as a bridging therapy to liver transplantation,
were successfully addressed using adequate immunosuppressants strategies and …

Simple Summary Hepatocellular carcinoma (HCC) is the most common primary liver tumor
in adults worldwide. Management of HCC has evolved substantially with the advent of …

Due to its widespread occurrence and high mortality rate, hepatocellular carcinoma (HCC) is
an abhorrent kind of cancer. Immunotherapy is a hot spot in the field of cancer treatment …

The use of immune checkpoint inhibitors (ICIs) targeting PD-L1/PD-1 and CTLA-4 has
transformed the oncology practice of hepatocellular carcinoma. However, only 25–30% of …